SPATS2 (spermatogenesis associated serine rich 2) is an RNA-binding protein that functions as an oncogene in multiple cancer types, particularly hepatocellular carcinoma (HCC). SPATS2 promotes cancer cell proliferation, migration, and metastasis through regulation of cell cycle progression, specifically preventing G1 arrest and reducing apoptosis 1. The protein is significantly overexpressed in HCC tissues compared to normal tissues and correlates with advanced TNM stages, vascular invasion, tumor multiplicity, and poor patient survival 12. SPATS2 expression is regulated by multiple epigenetic mechanisms, including DNA methylation, m6A modification, and histone modifications 3. The long noncoding RNA SNHG5 positively regulates SPATS2 by reducing DNMT3a expression, leading to SPATS2 hypomethylation 4. Additionally, miR-145-5p negatively regulates SPATS2 expression 1. SPATS2 shows clinical significance as a potential diagnostic and prognostic biomarker, with high expression serving as an independent risk factor for liver cancer (HR = 2.41 for overall survival) 2. The protein is also associated with immune cell infiltration in HCC and may serve as a therapeutic target 35.